Article

Ophthotech initiates expansion studies of wet AMD therapy

Ophthotech Corp. has initiated the first of several planned expansion trials, in addition to the ongoing E10030 (Fovista) combination therapy phase III clinical program.

 

New York-Ophthotech Corp. has initiated the first of several planned expansion trials, in addition to the ongoing E10030 (Fovista) combination therapy phase III clinical program.

The expansion trials will investigate the potential role of the anti-platelet derived growth factor (anti-PDGF) combination therapy in reducing sub-retinal fibrosis, addressing sub-optimal treatment response, and reducing treatment burden in patients with wet age-related macular degeneration (AMD) receiving anti-vascular endothelial growth factor (anti-VEGF) monotherapy.

More in this issue: Kala studying nanotechnology for RVO, DME, and MGD

The first expansion trial is a phase IIa open-label study investigating the potential role of anti-PDGF therapy in combination with anti-VEGF therapy in reducing sub-retinal fibrosis in patients with wet AMD.

“The initiation of the . . . expansion studies continues our commitment to advance scientifically driven therapeutic options to address an unmet medical need in AMD,” said David R. Guyer, MD, chief executive officer and board chairman of Ophthotech. “Sub-retinal fibrosis is associated with poor visual outcome in patients receiving anti-VEGF monotherapy for wet AMD.

 

NEXT: Page 2

 

“The inhibition of fibrosis is an urgent and unmet medical need in wet AMD,” he continued.

 

For more articles in this issue of Ophthalmology Times eReport, click here.

 

 

To receive weekly clinical news and updates in ophthalmology, subscribe to the Ophthalmology Times eReport.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.